Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!

Learn More
Banner

Pancreatic Cancer Resistant Cell Model

Pancreatic Cancer Resistant Cell Model

Chemotherapy resistance is one of the leading causes of pancreatic cancer (PC) therapy failure and eventual death. Effective cell models of drug resistance are critical to building translational bridges between in vitro and in vivo studies to make relevant discoveries. Alfa Cytology uses PC-related expertise and cutting-edge technology to develop highly repeatable and reliable drug-resistant cell models that can be used to gain valuable insights into tumor occurrence, progression, and therapy response.

Overview of Pancreatic Cancer-Resistant Cell Model

Statistics show that more than 90% of cancer deaths are related to drug resistance. Therefore, the persistence of drug resistance remains a major challenge in the development of PC therapies, leading to reduced drug response and disease recurrence. While efforts are underway to identify resistance mechanisms and develop new drugs and therapeutics to overcome them, the lack of physiologically relevant drug-resistant cancer model systems remains a major challenge.

The cells have strong drug resistance and proliferation ability, which is the reason why recurrent tumors are more aggressive.Fig. 1 Different mechanisms of drug resistance in pancreatic cancer. (Quiñonero F., et al., 2019)

Developing drug-resistant cell lines is critical to studying resistance mechanisms and identifying alternative treatment pathways. There are two forms of resistance to cancer, which are intrinsic resistance and acquired resistance.

Types Description
Intrinsic resistance Intrinsic resistance is present before treatment, giving cancer cells an inherent ability to survive in the presence of the drug. Poor initial response to therapy indicates possible intrinsic resistance.
Acquired resistance Acquired resistance occurs after an initial positive response to treatment. In this condition, cancer cells gradually acquire specific genetic abnormalities or protein alterations that eventually lead to non-response to treatment and cancer recurrence.

Our Services

The complexity of cancer genomics and tumor biology allows pancreatic cancer to develop new resistance mechanisms to existing or emerging cancer therapies. New cancer therapies are evaluated through expensive low-throughput animal studies and clinical trials. Therefore, there is an urgent need for complex, three-component, and multi-component in vitro cancer models that simulate the plasticity of tumor cells and tumor microenvironments.

Cell models are key for understanding resistance mechanisms and developing novel therapies. Alfa Cytology is working to develop state-of-the-art models of resistant pancreatic cancer cells to improve traditional drug-resistant models.

Models Descriptions Applications

Drug-Selected Resistant Cell Lines
This model works by exposing pancreatic cancer cells to a specific drug or therapy that increases in concentration over time and eventually creates a resistant cell line.
  • Helps understand how cancer cells adapt and evolve to resist therapy
  • Investigate the mechanisms behind resistance, explore new drug combinations, and develop targeted therapies to overcome resistance
  • Identify the genetic and molecular changes that drive drug resistance

Genetically Engineered Resistant Cell Lines
Genetically engineered drug-resistant cell lines are generated by introducing specific genetic changes into cancer cells to mimic the genetic changes observed in drug-resistant tumors.
  • Simulated tumors become resistant to targeted therapy
  • Helps elucidate molecular drivers of drug resistance, identify potential therapeutic targets, and test new therapeutic strategies

Why Choose Us?

Scientific Experience

Professional team of scientists and more than ten years of experience in pancreatic cancer

Customized Service

Tailored services dedicated to ensuring customer satisfaction

Data Security

Strictly keep confidential the client's project information and experimental data

Quick Reply

Our customer service representatives are available 24 hours a day from Monday to Sunday

Each type of cell model has its own advantages and limitations, and using a combination of several models can more comprehensively study drug resistance in pancreatic cancer and develop new treatments. If you are interested in our services, please contact us for more details. You can contact our staff directly and receive professional, reliable, and fast feedback.

Reference

  1. Quiñonero F, et al. The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview. Cancer Biol Med. 2019;16(4):688-699. doi:10.20892/j.issn.2095-3941.2019.0252
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.